These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15948332)

  • 21. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
    Gass A; Wilson J
    Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
    [No Abstract]   [Full Text] [Related]  

  • 22. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
    Goldman SA
    Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
    [No Abstract]   [Full Text] [Related]  

  • 23. A quantitative analysis of adverse events and "overwarning" in drug labeling.
    Duke J; Friedlin J; Ryan P
    Arch Intern Med; 2011 May; 171(10):944-6. PubMed ID: 21606101
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug industry is told to stop gifts to doctors.
    Pear R
    N Y Times Web; 2002 Oct; ():A1, A29. PubMed ID: 12474836
    [No Abstract]   [Full Text] [Related]  

  • 25. Expedited safety reporting requirements for human drug and biological products; correction--FDA. Final rule; correction.
    Fed Regist; 1998 Mar; 63(58):14611-2. PubMed ID: 10177754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment traps to avoid. Insured? You're money in the bank to the health-care system.
    Consum Rep; 2007 Nov; 72(11):12-7. PubMed ID: 17966565
    [No Abstract]   [Full Text] [Related]  

  • 27. Stanford to ban drug makers' gifts to doctors, even pens.
    Pollack A
    N Y Times Web; 2006 Sep; ():C2. PubMed ID: 16972375
    [No Abstract]   [Full Text] [Related]  

  • 28. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
    Shea LL; Hanson A; Guglielmetti TM; Levy K
    Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
    [No Abstract]   [Full Text] [Related]  

  • 29. FDA cracks down on labeling, initiates trial result reporting.
    Osborne R; Waltz E
    Nat Biotechnol; 2008 Nov; 26(11):1203-4. PubMed ID: 18997742
    [No Abstract]   [Full Text] [Related]  

  • 30. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postmarketing surveillance--lack of vigilance, lack of trust.
    Fontanarosa PB; Rennie D; DeAngelis CD
    JAMA; 2004 Dec; 292(21):2647-50. PubMed ID: 15572723
    [No Abstract]   [Full Text] [Related]  

  • 32. Pfizer to pay $430 million over promoting drug to doctors.
    Harris G
    N Y Times Web; 2004 May; ():C6. PubMed ID: 15290803
    [No Abstract]   [Full Text] [Related]  

  • 33. The drug safety system conundrum.
    Tiedt TN
    Food Drug Law J; 2007; 62(3):547-558. PubMed ID: 17915396
    [No Abstract]   [Full Text] [Related]  

  • 34. In article, doctors back ban on drug companies' gifts; concerns cited on quality of patient care.
    Harris G
    N Y Times Web; 2006 Jan; ():A14. PubMed ID: 16450472
    [No Abstract]   [Full Text] [Related]  

  • 35. Impossible? Outlawing state safety laws for generic drugs.
    Glantz LH; Annas GJ
    N Engl J Med; 2011 Aug; 365(8):681-3. PubMed ID: 21830958
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug withdrawals from the Canadian market for safety reasons, 1963-2004.
    Lexchin J
    CMAJ; 2005 Mar; 172(6):765-7. PubMed ID: 15767610
    [No Abstract]   [Full Text] [Related]  

  • 37. PLIVA v. Mensing: generic consumers' unfortunate hand.
    Lee SB
    Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916
    [No Abstract]   [Full Text] [Related]  

  • 38. Despite warnings, drug giant took long path to Vioxx recall.
    Berenson A; Harris G; Meier B; Pollack A
    N Y Times Web; 2004 Nov; ():A1, A32. PubMed ID: 15599982
    [No Abstract]   [Full Text] [Related]  

  • 39. The black box warning.
    Abourjaily HM; Rosenberg M
    J Mass Dent Soc; 2002; 51(3):54-6. PubMed ID: 12380043
    [No Abstract]   [Full Text] [Related]  

  • 40. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
    Karst KR
    Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.